MDM2 overexpression by pediatric ALL cells at initial diagnosis has been linked to poor response to therapy. In the present study, we evaluated the incidence of MDM2 overexpression by ALL cells from pediatric patients at first relapse and compared MDM2 protein levels with in vitro response to adriamycin and with duration of initial complete remission (CR1). Since an important role of MDM2 in enhancing cell proliferation and survival appears to be inhibition of p53 activity, we also evaluated the status of p53 in these patients' leukemic cells. MDM2 protein levels were determined by Western blot analysis of leukemic bone marrow cells obtained from 42 patients with B cell precursor (BCP) ALL who relapsed during or following therapy on standard POG ALL protocols. Twelve of 42 (29%) cases have MDM2 levels у10-fold higher than those detected in normal bone marrow mononuclear (NMMC) cells, which express relatively low levels of protein. Thirty cases (71%) expressed MDM2 at levels Ͻ10-fold those in NMMC, including 24 MDM2-negative cases (57%). P53 mutations were detected by single-strand conformation polymorphism analysis in two cases. Overexpression of MDM2 (у10-fold) was significantly correlated with adriamycin resistance and decreased duration of CR1. Eight of 12 (75%) overexpressers showed high levels of in vitro resistance to adriamycin, compared to four of 30 (13%) nonoverexpressers (P Ͻ 0.005). The median CR1 for MDM2 overexpressers was 20.5 months (range: 3-75 months) compared to 41 months (range: 8-98 months) for non-overexpressers (P Ͻ 0.01). Four of 42 patients failed to achieve CR following reinduction: leukemic cells from three of these patients either overexpressed MDM2 or contained a mutant p53. These results indicate that overexpression of MDM2 plays a significant role in refractory pediatric ALL and is associated with early relapse, adriamycin resistance, and failure to respond to re-induction therapy. Leukemia (2000) 14, 61-67.
Introduction
MDM2 is considered a new type of proto-oncogene due to the ability of its product to inhibit p53 tumor-suppressor function. 1, 2 Previous studies have shown that MDM2 contributes to therapy-resistant disease by binding to p53 and abrogating its cell-cycle arrest and apoptotic function. [3] [4] [5] Moreover, recent studies have proposed additional mechanisms for MDM2 in cell transformation, cell-cycle regulation and apoptosis other than those resulting from p53 interactions. MDM2 splice variants lacking amino-terminal p53-bindingdomain sequences have been identified in several tumors, including late-stage ovarian and bladder carcinomas. 6 These variants show loss of p53-binding but retain carboxy-terminal zinc-finger domains, indicating that an oncogenic activity unrelated to inactivation of p53 is encoded by the truncated MDM2. Consistent with these observations, overexpression of N-terminally truncated MDM2 in p53-null cells resulted in transformation. 6 Overexpression of MDM2 in the mammary gland led to uncontrolled entry into S-phase, polyploidy, and tumor formation in p53-null as well as wt-p53+ mice. 7 Furthermore, overexpression of MDM2 in transgenic mice lacking a functional p53 gene is highly tumorigenic, 8 further indicating a p53-independent role for MDM2 in tumorigenesis. Therefore, MDM2 can function through both p53-dependent and p53-independent pathways to induce cell proliferation and to enhance cell survival.
MDM2 mRNA and/or protein are overexpressed in a variety of neoplasms, including acute leukemia. [9] [10] [11] [12] [13] [14] Overexpression of MDM2 has been reported in 15-25% of ALL patients at diagnosis and is associated with expression of a wild-type p53 gene and poor response to induction therapy. [12] [13] [14] However, there have been no extensive studies of the incidence or prognostic significance of MDM2 overexpression in pediatric ALL at relapse. Although aggressive re-induction therapy has enabled the majority of relapsed patients to achieve a complete second remission (CR2), approximately 10-20% of relapsed ALL patients fail to attain CR2 due to resistant disease. 15 The role of MDM-2 overexpression in the failure of these patients to respond to chemotherapy has not been reported.
The present study was prompted by our observation that MDM2 overexpression was associated with adriamycin (doxorubicin) resistance in several B cell-precursor acute lymphoblastic leukemia (BCP-ALL) and T cell ALL cell lines established from pediatric patients in relapse. The goal of this study was therefore to determine the incidence and prognostic significance of MDM2 overexpression in primary relapsed ALL cells, and to evaluate the association between MDM2 overexpression, in vitro resistance to adriamycin, and response to re-induction therapy. Access to bone marrow specimens from BCP-ALL patients treated at Pediatric Oncology Group institutions enabled us to examine a relatively large number of cases.
Materials and methods

Patient cells
Patients included in this study were treated for relapsed BCP-ALL (first relapse) on Pediatric Oncology Group (POG) protocol 9411, 'Treatment of Relapsed Non-T Non-B Acute Lymphoblastic Leukemia with Intensive Chemotherapy' conducted between December 1995 and April 1997. Patients were treated with re-induction therapy consisting of PVDA (prednisone, vincristine, daunorubicin or adriamycin, and asparaginase) and consolidation therapy (ifosfamide/etoposide followed by cytarabine/idarubicin). Response following induction and consolidation therapy was rated as either com-plete remission (CR, M1 marrow with Ͻ5% blasts), partial remission (PR, M2 marrow with 5-25% blasts) or no response (M3 marrow with Ͼ25% blasts).
Following informed consent, pre-treatment bone marrow specimens from patients treated at multiple institutions were sent by overnight courier to Emory University. Patients were not selected and represent the overall population at first relapse. Mononuclear cells were separated by centrifugation on Ficoll-Hypaque (1.077 g/ml), washed twice in phosphatebuffered saline (PBS), and resuspended at 10 6 /ml in RPMI 1640 containing 10% fetal bovine serum (FBS). The cells were incubated on plastic petri dishes for 1 h at 37°C to remove monocytes, and nonadherent cells were recovered by gently washing the dishes. All samples contained Ͼ90% leukemic cells post-Ficoll.
XTT assay
The effect of adriamycin on leukemic bone marrow cells obtained from relapsed patients was determined by the XTT cytotoxicity assay. Cleavage of XTT (a tetrazolium salt) by mitochondrial-associated dehydrogenase enzymes in metabolically active cells yields a colored formazan product that can be measured spectrophotometrically. The concentration of the products is directly proportional to the viability of the cells. 16 Following treatment with different concentrations of adriamycin, cells were cultured in 96-well microtiter plates and incubated for 44 h. XTT (25 g/well) was then added and cells were incubated for an additional 4 h. The optical density (OD) of the wells was then read with a microplate reader at a test wavelength of 450 nm and a reference wavelength of 620 nm. Appropriate controls lacking cells were included to determine background absorbance.
Western blot assay
Purified primary bone marrow leukemic cells and normal (ie control) bone marrow mononuclear cells (NMMC) from an ALL patient during remission were lysed in a buffer composed of 150 mM NaCl, 50 mM Tris (pH 8.0), 5 mM EDTA, 1% (v/v) Nonidet p-40, 1 mM phenylmethylsulfonyl fluoride, 20 g/ml aprotinin, and 25 g/ml leupeptin for 30 min at 4°C. After clarification, equal amounts of protein extracts were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to nitrocellulose paper. After blocking with buffer containing 20 mM Tris-HCl (pH 7.5) and 500 mM NaCl, 5% non-fat milk for 1 h at room temperature, the filter was incubated with specific antibodies to MDM2 (Oncogene Science Inc, Uniondale, NY, USA) for 1 h at room temperature, followed by HRP-labelled secondary antibody. Blots were developed using a chemiluminescent detection system (ECL; Amersham Life Science, Buckinghamshire, UK). After stripping, the filter was reprobed with an anti-actin antibody (Calbiochem, Cambridge, MA, USA) as a control for equal protein loading and protein integrity. In addition, the MDM2 levels of protein expression in each sample were compared by densitometry.
Single-strand conformation polymorphism (SSCP) analysis and DNA sequencing
Genomic DNA was prepared from each sample using a DNA Isolation Kit (Puregene, Minneapolis, MN, USA) following the manufacturer's instructions. p53 exons 5-8, which are commonly mutated in tumor cells, were analyzed for point mutations by SSCP as described in our previous study. 11 Briefly, genomic DNA (100 ng) was subjected to PCR amplification using 10 pmol of each primer, 2.5 M dNTPs, 1 Ci of alpha-32 P dCTP (NEN; specific activity, 3000 Ci/mmol) and 0.5 unit of Taq polymerase in a buffer containing 10 mM Tris.Hcl (pH 8.8), 50 mM KCl, 1 mM MgCl 2 and 0.01% gelatin. Thirty cycles of denaturation (94°C), annealing (55°C) and extension (72°C) were performed in an automated heat-block (Minicycler, MJ Research Inc, Watertown, ME, USA). PCR products were diluted 1/20 in 95% formamide (containing 20 mM EDTA, 0.05% bromophenol blue, and 0.05% xylene cyanol), heated to 90°C for 3 min, chilled on ice, and immediately loaded (3 l) on to a 6% acrylamide/TBE gel containing 5% (vol/vol) glycerol. Gels were run at 8 W for 12-15 h at room temperature. Autoradiography was performed for 6-24 h.
PCR products that demonstrated an aberrant migration pattern in the SSCP autoradiograph relative to the wild-type gene were analyzed for nucleotide sequence. Before sequencing, the targeted DNA was PCR-amplified, using 1 g of genomic DNA and 50 pmol of each primer in a final volume of 100 l. PCR conditions and number of amplification cycles were as described for the SSCP analysis, omitting the 32 P-dCTP. PCR products were separated by electrophoresis in an agarose gel and purified using the DNA Purification System (Promega, Madison, WI, USA). Purified cDNA was sequenced using a modification of the dideoxy chain-termination procedure (Double-stranded DNA Cycle Sequencing System, Life Technologies, Gaithersburg, MD, USA) following the manufacturer's recommendations.
Statistical analysis
For testing the relationship between MDM2 expression, drugresistance, and duration of CR1 in 2 × 2 tables, the chi-square test was utilized. The Student's t-test was used for comparison of means between groups. Table 1 summarizes clinical and cytogenetic data for 42 patients with relapsed BCP-ALL, and Table 2 contains results of gene expression and adriamycin-resistance studies, together with duration of first complete remission (CR1) and response to re-induction therapy. Adriamycin resistance (expressed as the IC 50 value, ie the concentration required to reduce cell viability by 50% in a 48 h XTT assay) was classified as either high (group 1: IC 50 Ͼ1 M, n = 12), intermediate (group II: IC 50 = 0.2-1 M, n = 9) or low (group III: IC 50 Ͻ0.2 M, n = 21). All but one of the 42 patients received a full course of re-induction chemotherapy; the former patient (UPN1) died during treatment. Four patients failed to achieve a complete second remission after receiving consolidation therapy; three of these patients were in group I (UPN4, 7, 11) and one in group III (UPN 32).
Results
Patient characteristics and adriamycin sensitivity
Incidence of abnormalities in MDM2/p53 expression in relapsed BCP-ALL
In order to investigate whether in vitro drug resistance in relapsed BCP-ALL was correlated with abnormalities in Figures 1 and 2) ; mutations in these codons have been previously reported in ALL. 11 No mutations in exons 5, 6 and 8 were detected in any of the leukemic specimens. One of the patients with p53 mutations (UPN32) was MDM2-negative; the other patient (UPN4) expressed 15-fold increased MDM2. Presence of p53 mutations was not obviously correlated with in vitro adriamycin resistance, since leukemic cells from one of the two mutp53+ cases (UPN32) were sensitive to adriamycin (IC 50 Ͻ0.2 M). However, both mut-p53+ patients failed re-inducLeukemia tion therapy, and a definitive conclusion could not be made due to the small number of mut-p53+ patients evaluated.
In contrast to mutations in p53, marked overexpression of MDM2 (у10-fold relative to normal bone marrow mononuclear cells, NMMC) was frequently observed in relapsed BCP-ALL patients and was highly associated with adriamycin resistance. MDM2 protein was expressed in 18 of the 42 cases, as detected by Western blot assay. The level of MDM2 protein in these patients was compared densitometrically to that of NMMC, which express relatively low amounts of MDM2. Twelve of the 42 (29%) specimens expressed high MDM2 levels (у10-fold normal), and the remainder expressed either Ͻ10-fold increased protein relative to NMMC or were MDM2-negative ( Figure 3 and Table 2 ). Ten of 12 specimens overexpressing MDM2 (у10 ×) showed increased in vitro resistance to adriamycin. Of these 10 cases, eight (80%) were Table 2 Comparison of molecular and in vitro drug resistance data with clinical response for patients in highly resistant to adriamycin (IC 50 Ͼ1 M), compared to four of 30 (13%) MDM2-negative cases (P = 0.001, Chi-square test) (Tables 2 and 3) .
To address the question of whether MDM2 overexpression was acquired during therapy or present at initial diagnosis, we SSCP analysis of p53 mutations in leukemic cells from seven ALL patients. Radiolabeled PCR-amplified genomic DNA fragments corresponding to each exon were denatured and separated on acrylamide/glycerol gel. Arrows indicate DNA fragments containing point mutations in exon 7.
Figure 2
Sequence analysis of p53 mutations in leukemic cells from two relapsed ALL patients. Sequences from exon 7 are shown for patients 4 and 32, respectively. Arrows point to bands corresponding to point mutations (transitions) in codon 248 and 245, respectively.
performed Western blotting on cryopreserved bone marrow samples from nine of the above cases at diagnosis. Two (22%) expressed MDM2, and one of these showed Ͼ10-fold increased expression; both patients overexpressed MDM2 at relapse. Seven cases were negative for MDM2 expression at diagnosis, and four of these patients overexpressed MDM2 at relapse (data not shown). This suggests that in some cases, MDM2 overexpression is not present at diagnosis but is acquired during therapy.
Clinical significance of abnormalities in MDM2/p53 expression
Overexpression of MDM2 (Ͼ10 ×) was correlated with decreased duration of first complete remission and refractory disease. Median duration of CR1 in MDM2-overexpressing cases was 20.5 months (mean = 25 months), compared to 41 months (mean = 45 months) in MDM2 non-overexpressing cases (P = 0.011, t-test). There was a significant association 
Table 3
Correlation of MDM2 overexpression with adriamycin resistance and duration of initial complete remission (CR1, in months) between overexpression of MDM2 and CR1 Ͻ24 months: 60% of cases with CR1 Ͻ24 months overexpressed MDM2, compared with 19% of cases with CR1 Ͼ24 months (P = 0.02, chi-square test). MDM2 overexpression was also associated with poor response to re-induction therapy. Four of 42 patients failed to achieve CR following re-induction/consolidation therapy and were classified as partial responders (PR, with 5-25% bone marrow blasts). Three of these refractory patients were in group I (IC 50 Ͼ1 M) and one in group III (IC 50 Ͻ0.2 M) ( Table 1 ). Leukemic cells from two of the four PR patients Leukemia (UPN4 and UPN11) overexpressed MDM2, while blasts from the remaining two PR patients (UPN7 and UPN32) were MDM2-negative but one (UPN32) contained a mutant p53. Consistent with the association between MDM2 overexpression and poor prognosis, there was a significant correlation between MDM2 overexpression (Ͼ10 ×) and adriamycin resistance (IC 50 Ͼ1 M; P = 0.001, chi-square test).
Discussion
Approximately 25-30% of children with ALL on current treatment protocols will relapse with chemotherapy resistant disease. 15 A number of factors may contribute to refractory disease, including overexpression of the MDR1 gene, although this mechanism appears to be more common in pediatric acute myeloblastic leukemia than in ALL. 17 Additionally, alterations in molecular targets of specific drugs may result in resistance to this drug. For instance, elevated or decreased levels of topoisomerase II may cause resistance to drugs which inhibit the function of this enzyme, including adriamycin, although studies of primary ALL cells have not shown a significant correlation between drug sensitivity and the level of topoisomerase IIa or IIb expression in these cells. 18, 19 Genetic alterations may also contribute to chemotherapy resistance, including activation and overexpression of cellular oncogenes, as well as inactivation of tumor suppressor genes.
In the present study, we have performed the first extensive analysis of MDM2 overexpression in pediatric ALL patients at relapse. We have quantitated the level of MDM2 expression in leukemic cells from 42 pediatric BCP-ALL patients at first relapse. The MDM2 gene product has been implicated as a poor prognostic factor for ALL at initial diagnosis by several studies. An initial study by Bueso-Ramos et al 10 reported MDM2 overexpression in three of seven (42%) adult ALL cases at initial diagnosis, as well as in a number of adult AML patients. Marks et al 13 later studied MDM2 protein expression at diagnosis in good-outcome ALL patients (ie those in longterm continuous remission) and poor-outcome patients (those who failed to achieve long-term remission or relapsed within 6 months). MDM2 overexpression was detected in approximately 30% (5/17) poor-outcome patients but was not found in good-outcome patients. Furthermore, all five MDM2-overexpressing patients also expressed a wt-p53 gene, supporting the idea that one consequence of overexpressed MDM2 in refractory ALL may be inhibition of p53 function. According to this mechanism, MDM2 binds the transcriptional activation domain of p53 and blocks its ability to regulate target genes. [1] [2] [3] [4] [5] The incidence of MDM2 overexpression has not been extensively investigated in relapsed pediatric ALL. Using Western blot analysis, we detected high levels of MDM2 expression (Ͼ10-fold normal) in leukemic cells from 12 of 42 (29%) childhood BCP-ALL cases at first relapse. All except one of these cases had a wt-p53 phenotype. These results indicate that MDM2 is overexpressed in a significant number of relapsed childhood BCP-ALL cases with wt-p53 phenotype.
This observation has potential clinical importance, since we have found that p53 mutations appear to be relatively infrequent in childhood BCP-ALL at first relapse (5% of cases studied). A similarly low incidence of p53 mutations has been detected in pediatric BCP-ALL at diagnosis. In a large retrospective study by Wada et al 20 of newly diagnosed pediatric patients with ALL, only five of 264 BCP-ALL cases (1.6%) had p53 mutations. Previously, there have been no extensive studies of p53 mutation rates in relapsed BCP-ALL reported; in the Wada study, two of 15 (13%) relapsed ALL patients had somatic mutations in their leukemic cells. In contrast, Diccianni et al 21 found a 24% incidence (12/51 cases) of mutated p53 in pediatric T-ALL patients at first relapse, although p53 mutations were identified in only 11% of these cases (1/9 examined) at diagnosis.
Although there appears to be a low incidence of p53 mutations in BCP-ALL at relapse, our data suggests that overexpression of MDM2 in BCP-ALL has a similar effect to p53 loss-of-function mutations in contributing to refractory disease. This is reflected in the significant association between MDM2 overexpression, adriamycin resistance, decreased duration of CR1, and re-induction failure. Overexpression of MDM2 was associated with in vitro adriamycin resistance in 67% of resistant cases (P = 0.001) and with CR1 Ͻ24 months in 60% of these cases (P = 0.02). Furthermore, although only four of 42 patients failed to achieve complete remission following re-induction therapy, leukemic cells from two of these patients overexpressed MDM2; cells from the other two patients were MDM2-negative but one of them expressed a mutant-p53 gene. Based on our studies of cryopreserved bone marrow specimens at initial diagnosis, MDM2 overexpression can in some cases be acquired during therapy.
These results indicate the importance of designing therapies to inhibit MDM2 expression in pediatric ALL cells overexpressing this protein.
In preliminary experiments, we have found that MDM2 antisense directed against an N-terminal region of the gene can decrease MDM2 protein levels and significantly increase sensitivity to adriamycin in an MDM2-overexpressing ALL cell line (manuscript in preparation). We are also investigating the effects of specifically inhibiting MDM2 expression on the expression of other cell proliferation and survival genes, as well as on the sensitivity of antisensetreated cells to other apoptosis-inducing agents.
